Clinical implications
AF is the most common cardiac arrhythmia affecting over 33 million
people worldwide, and the incidence of AF is
increasing.17 Patients with AF have an increased risk
of stroke, heart failure, cardiovascular hospitalization, and
mortality.18 Although catheter ablation can
effectively treat some patients, the long-term success rate is low, and
the recurrence rate is high and there has been no progress in the
development of new antiarrhythmic drugs in recent
years..19,20 Our present study found that the
expression of KCa3.1 was heterogeneous in different
parts of the rabbits atrium. The high expression of
KCa3.1 in the PVs and SVC is an important mechanism for
triggering activity. Inhibition of KCa3.1 significantly
suppressed triggering activity. Taken together, our findings provide an
experimental basis for clinical AF treatment and drug development.